Antiphospholipid antibodies linked to heart attacks

| October 23, 2018

article image
Levels of antiphospholipid antibodies, which are associated with rheumatic diseases, are also elevated in myocardial infarction without any autoimmune co-morbidity. Antiphospholipid antibodies (aPL) are a group of antibodies that target endogenous tissue, including the fat molecule cardiolipin and the plasma protein β2glycoprotein-I. Cardiolipin is found in the membranes of blood vessel and blood platelet cells, whereas β2glycoprotein-I is found in the blood and is thought to help the body rid itself of dead cells.

Spotlight

Advantia Health

Advantia Health is an innovative fast growing healthcare delivery company, founded and led by a passionate group of entrepreneurs and backed by top tier healthcare investors. Sean Glass, Founder & CEO of Advantia Health, previously founded and grew a financial technology company to more than a billion dollar valuation. Advantia Health provides high quality, high value care using technology and highly efficient outpatient facilities. In a little over three years, the company has grown to serve more than 100,000 customers and is on a path to serving many more in the years to come. Advantia’s investors include Deerfield Management, Life Force Capital, and individuals with significant health care, technology, and finance expertise.

OTHER ARTICLES

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 20, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Advantia Health

Advantia Health is an innovative fast growing healthcare delivery company, founded and led by a passionate group of entrepreneurs and backed by top tier healthcare investors. Sean Glass, Founder & CEO of Advantia Health, previously founded and grew a financial technology company to more than a billion dollar valuation. Advantia Health provides high quality, high value care using technology and highly efficient outpatient facilities. In a little over three years, the company has grown to serve more than 100,000 customers and is on a path to serving many more in the years to come. Advantia’s investors include Deerfield Management, Life Force Capital, and individuals with significant health care, technology, and finance expertise.

Events